Search
Melanoma
go.drugbank.com/conditions/DBCOND0020306Synonyms: Malignant melanoma, no ICD-O subtype, Malignant melanoma, no International Classification of Diseases for Oncology subtypeAcute Non-Lymphocytic Leukemia
go.drugbank.com/conditions/DBCOND0038781Drugs: TioguanineSynonyms: Acute myeloid leukemia, no ICD-O subtype (morphologic abnormality), Acute myeloid leukemia, no International Classification of Diseases for Oncology subtypeCutaneous Melanoma
go.drugbank.com/conditions/DBCOND0040978Drugs: IpilimumabSynonyms: Malignant melanoma, no ICD-O subtype, Malignant melanoma, no International Classification of Diseases for Oncology subtypeChronic Phase Chronic Myeloid Leukemia
go.drugbank.com/conditions/DBCOND0057382Synonyms: Chronic myelogenous leukemia, no ICD-O subtype, Chronic myelogenous leukemia, no ICD-O subtype (morphologic abnormality)Myeloblastic Leukemia
go.drugbank.com/conditions/DBCOND0042219Drugs: DaunorubicinSynonyms: Myeloid leukemia, no ICD-O subtype (morphologic abnormality), Myeloid leukemia, no International Classification of Diseases for Oncology subtypeDurvalumab
go.drugbank.com/drugs/DB11714ApprovedInvestigational≥ 1% of tumour cells and there was no observable disease progression following platinum-based chemoradiation therapy. … [L12621] In September 2018, durvalumab was approved by the EMA for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC), only if PD-L1 is expressed in
Daptomycin
go.drugbank.com/drugs/DB00080ApprovedInvestigational[A231384] Early work on developing daptomycin was abandoned due to observed myopathy but was resumed in 1997 when Cubist Pharmaceuticals Inc. licensed daptomycin; it was found that a once-daily dosing … [A231379] Daptomycin was approved by the FDA on September 12, 2003, and is marketed under the name CUBICIN® by Cubist Pharmaceuticals LLC (Merck & Co.).[L32534]
Products: CUBICIN® 350 MG POLVO PARA SOLUCIÓN INYECTABLE O INFUSIÓN, CUBICIN® 500 MG POLVO PARA SOLUCION INYECTABLE O INFUSIONTechnetium Tc-99m nofetumomab merpentan
go.drugbank.com/drugs/DB09336ApprovedWithdrawnIt was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.[L1650, L1082] … [FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14, 1992.
Capmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigational[L13347] Capmatinib was approved by Health Canada on June 8, 2022.[L42015] … [L13347] The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same
Categories: MATE 2-K InhibitorsLuliconazole
go.drugbank.com/drugs/DB08933ApprovedInvestigationalLuliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. … It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.